09/600493

```
[illegible]


 FILE 'HOME' ENTERED AT 14:14:26 ON 11 NOV [illegible]

     INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, AQUASCI,
     BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO,
CABA,
     CANCERLIT, CAPLUS, CEABA, CEN, CIN, CONFSCI, DDFB, DDFU, DGENE, DDFU,
     DGENE, DRUGB, DRUGLAUNCH, [illegible], ...' ENTERED AT 14:15:4[illegible] ON 11 NOV
     [illegible]
                SEA (DNA) VACCIN? OR DNA (A) VACCIN? OR NUCLEIC ACID VA? OR
VA??
                ---------
             4?4   FILE ADISALERTS
             [illegible]   FILE ADISINSIGHT
             [illegible]   FILE AGRICOLA
             [illegible]   FILE AIDSLINE
             [illegible]   FILE ANABSTR
             [illegible]   FILE AQUASCI
             [illegible]   FILE BIOBUSINESS
             [illegible]   FILE BIOCOMMERCE
            2492   FILE BIOSIS
            2180   FILE BIOTECHABS
            2160   FILE BIOTECHDS
            [illegible]   FILE BIOTECHNO
             475   FILE CABA
             [illegible]   FILE CANCERLIT
            [illegible]   FILE CAPLUS
             [illegible]   FILE CEABA
             [illegible]   FILE CEN
             305   FILE CIN
              84   FILE CONFSCI
              35   FILE DDFB
             [illegible]   FILE DDFU
            [illegible]   FILE DGENE
             [illegible]   FILE DRUGB
            [illegible]   FILE DRUGLAUNCH
             [illegible]   FILE DRUGNL
             [illegible]   FILE DRUGU
              66   FILE EMBAL
            2053   FILE EMBASE
            1062   FILE ESBIOBASE
               7   FILE FROSTI
               4   FILE FSTA
             [illegible]   FILE GENBANK
               5   FILE HEALSAFE
             [illegible]   FILE IFIPAT
             [illegible]   FILE JICST-EPLUS
            [illegible]   FILE LIFESCI
             [illegible]   FILE MEDICONF
            [illegible]   FILE MEDLINE
               [illegible]   FILE NIOSHTIC
              [illegible]   FILE NTIS
               [illegible]   FILE OCEAN
              [illegible]   FILE PHAR
               [illegible]   FILE PHIC
             [illegible]   FILE PHIN
            [illegible]   FILE PROMT
            [illegible]   FILE SCISEARCH
```

```
          [illegible]   FILE TOXLINE
          [illegible]   FILE TOXLIT
          [illegible]   FILE USPATFULL
          [illegible]   FILE WPIDS
          [illegible]   FILE WPINDEX
L1             [illegible] VACCIN[illegible] OF DNA [illegible] VACC[illegible] OF NUCLEIC ACID VACC[illegible] OR
VACC[illegible]
              ---------

     FILE 'HOME, CAPLUS, BIOSIS, MEDLINE, EMBASE, USPATFULL, SCISEARCH'
     ENTERED AT 14:[illegible]:55 ON [illegible] NOV [illegible]
L2         [illegible] S [illegible] VACCIN[illegible] OF DNA OR VACC? OF NUCLEIC ACID VACC? OR
VACCINA
L3         [illegible] S RNA VIR. OR [illegible] OR FLAVIVIR. OR HEPATITIS [illegible] OR HCV OR
H
L4         [illegible] S L2 AND L3
L5         [illegible] S L2 (A) L3
L6         4[illegible] S L4 AND [illegible]<1998[illegible]
L7         [illegible] DUP REM L6 ([illegible] DUPLICATES REMOVED)
L8          1[illegible] S L7 (P) (STRUCTURAL PROTEINS OR NS? OR POLYMERASE OR TRANSCRIP
L9           [illegible] S L7 (P) STRUCTURAL PROTEINS
L10          [illegible] S L7 (P) STRUCTURAL PROTEIN
L11          9 S L7 AND STRUCTURAL PROTEINS
L12          9 S L7 AND POLYMERASE
L13          4 S L7 AND PROTEASE
L14          [illegible] S L7 AND TRANSCRIPTASE
L15            S L7 AND HELICASE
L16        53[illegible] S D HIS
L17          3 S L7 AND NS?
L18         14 S L11 OR L12
L19         1[illegible] S L11 OR L12 OR L13 OR L14 OR L17
L20         1[illegible] DUP REM L19 ([illegible] DUPLICATES REMOVED)
L21          2 S L7 AND (NON STRUCTURAL PROTEINS OR NONSTRUCTURAL PROTEINS)
L22          9 S L1[illegible] OR L1[illegible] OR L14 OR L21

=> d l22 ibib abs


L22  ANSWER 1 OF 9  CAPLUS  COPYRIGHT [illegible] ACS
ACCESSION NUMBER:         1995:61519[illegible]  CAPLUS
DOCUMENT NUMBER:          123:31226
TITLE:                    Peptides derived from the hepatitis B virus DNA
                       polymerase that induce a cytotoxic T
                          lymphocyte response to the virus
INVENTOR(S):              Chisari, Francis V.
PATENT ASSIGNEE(S):       Scripps Research Institute, USA
SOURCE:                   PCT Int. Appl., [illegible]4 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO [illegible]       A1   [illegible]      WO 1994-[illegible]    [illegible]
         W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, FI, GB,
             GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, [illegible], [illegible],
VN
         RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,
             NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,
TG
     CA [illegible]       AA   [illegible]      CA 1994-[illegible]    [illegible]
     AU [illegible]       A1   [illegible]      AU 1994-[illegible]    [illegible]
     AU [illegible]       B2   [illegible]
```

```
     EP [illegible]            A1   [illegible]       EP 1994-925160   1994[illegible]
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
SE
     JP [illegible]            T2   [illegible]       JP 1994-[illegible]   [illegible]
     US [illegible]            A    [illegible]       US 1995-416[illegible]   [illegible]
     US [illegible]            A    [illegible]       US 1995-4[illegible]   [illegible]
PRIORITY APPLN. INFO.:                               US 1993-[illegible]   [illegible]
                                                     US 1991-749540   19910826
                                                     US 1992-935898   19920826
                                                     WO 1994-US8685   19940801
                                                     US 1995-416950   19950404
AB   Peptides are used to define epitopes that stimulate HLA-restricted
     cytotoxic T lymphocyte activity against hepatitis B virus antigens.  The
     peptides are derived from regions of HBV DNA polymerase, and are
     particularly useful in treating or preventing HBV infection, including
     methods for stimulating the immune response of chronically infected
     individuals to respond to HBV antigens.


 => d [illegible] 1-4 ibib abs


L3   ANSWER [illegible] OF [illegible]  CAPLUS  [illegible]  ACS
ACCESSION NUMBER:         [illegible]  CAPLUS
DOCUMENT NUMBER:          123:[illegible]
TITLE:                    Peptides derived from the hepatitis B virus DNA
                        polymerase that induce a cytotoxic T
                          lymphocyte response to the virus
INVENTOR(S):              Chisari, Francis V.
PATENT ASSIGNEE(S):       Scripps Research Institute, USA
SOURCE:                   PCT Int. Appl., 64 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   [illegible]
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 951[illegible]           A1   1995020[illegible]      WO 1994-US8685   19940801
         W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB,
             GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW,
             NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,
VN
         RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,
             NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,
TG
     CA 2168583        AA   19950209      CA 1994-2168583  19940801
     AU 9475184        A1   1995022[illegible]      AU 1994-75184    19940801
     AU [illegible]           B2   [illegible]
     EP 726758         A1   19960821      EP 1994-925160   19940801
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
SE
     JP [illegible]1165        T2   1997022[illegible]      JP 1994-506053   19940801
     US [illegible]        A    [illegible]      US 1995-416950   19950404
     US [illegible]        A    [illegible]      US 1995-4[illegible]   [illegible]
PRIORITY APPLN. INFO.:                           US 1993-[illegible]   [illegible]
                                                 US 1991-749540   [illegible]
                                                 US 1992-[illegible]   [illegible]
                                                 WO 1994-US8685   [illegible]
                                                 US 1995-416950   [illegible]
AB   Peptides are used to define epitopes that stimulate HLA-restricted
     cytotoxic T lymphocyte activity against hepatitis B virus antigens.  The
     peptides are derived from regions of HBV DNA polymerase, and are
     particularly useful in treating or preventing HBV infection, including
     methods for stimulating the immune response of chronically infected
```

individuals to respond to HBV antigens.

L4 ANSWER [illegible] OF [illegible] BIOSIS COPYRIGHT [illegible] BIOSIS
ACCESSION NUMBER: [illegible] BIOSIS
DOCUMENT NUMBER: PREV[illegible]
TITLE: Rapid cloning of [illegible] fragments directly from **lentivirus**-infected macaque serum: Utility for **DNA vaccination**.
AUTHOR(S): Holterman, Lennart; Ten Haaft, Peter; Niphuis, Henk; Heeney, Jonathan
CORPORATE SOURCE: Dep. Virol., Lab. Viral Pathogenesis, Biomed. Primate Res. Centre, Lange Kleiweg [illegible] Netherlands
SOURCE: Brown, F. (Editor); Norrby, E. (Editor); Burton, D. (Editor); Mekalanos, J. (Editor). Vaccines (Cold Spring Harbor), ([illegible]) [illegible], pp. [illegible]. Vaccines [illegible] Cold Spring Harbor; Molecular approaches to the control of infectious diseases.
Publisher: Cold Spring Harbor Laboratory Press 10 Skyline Drive, Plainview, New York 11803, USA.
Meeting Info.: Thirteenth Meeting Cold Spring Harbor, New York, USA September [illegible], [illegible]
ISSN: [illegible]. ISBN: 0-87969-4[illegible]-3.
DOCUMENT TYPE: Book; Conference
LANGUAGE: English

L4 ANSWER [illegible] OF [illegible] BIOSIS COPYRIGHT [illegible] BIOSIS
ACCESSION NUMBER: [illegible] BIOSIS
DOCUMENT NUMBER: PREV[illegible]
TITLE: Five-year follow-up of a prospective randomized trial of **hepatitis B** recombinant **DNA** yeast **vaccine** vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses.
AUTHOR(S): Lai, Ching-Lung (1); Wong, Benjamin Chun-Yu; Yeoh, Eng-Kiong; Lim, Wai-Ling; Chang, Wai-Kwan; Lin, Hsiang-Ji
CORPORATE SOURCE: (1) Dep. Med., Univ. Hong Kong, Queen Mary Hosp. Hong Kong
SOURCE: Hepatology, ([illegible]) Vol. 18, No. 4, pp. [illegible].
ISSN: [illegible].
DOCUMENT TYPE: Article
LANGUAGE: English

AB In a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-mu-g doses of **hepatitis B** recombinant **DNA** yeast **vaccine** at 0 and 1 mo (group 1), three 5-mu-g doses of **hepatitis B** recombinant **DNA** yeast **vaccine** at 0, 1 and 6 mo (group 2) or three 10-mu-g doses of plasma-derived hepatitis B vaccine (group 3). The HBs antibody response rate at 8 mo was between 93% and [illegible]; it was AM 75% to [illegible] at 5 yr in all three groups. Geometric mean titers at 1 yr were 83, 1,095 and [illegible] mIU/ml in groups 1, 2 and 3, respectively. These values had decreased after 5 yr to [illegible] and [illegible] mIU/ml. Subjects in group 1 showed a significantly less proportional drop in geometric mean titer at the fifth year than did subjects in group 2 (p [illegible]) or group 3 (p [illegible]). None of the children developed HBc antibody, even after 5 yr of follow-up. We noted 4[illegible] episodes of significantly increased HBs antibody titers, probably due to anamnestic response, even when the titers had dropped to low levels. The mean age at which anamnestic response occurred was [illegible] yr. We conclude that [illegible] the recombinant vaccine and plasma-derived vaccine are comparable in safety and immunogenicity, [illegible] two doses of vaccine was as effective in preventing hepatitis B infection as three doses, despite lower HBs antibody titers; [illegible] anamnestic responses occurred most frequently at [illegible] yr after [illegible]; and [illegible] booster [illegible] was not necessary at 5 yr, [illegible]

L[illegible] ANSWER 4 OF [illegible] MEDLINE
ACCESSION NUMBER: [illegible] MEDLINE
DOCUMENT NUMBER: [illegible]
TITLE: Characterization of hepatitis B virus DNA
polymerase.
AUTHOR: Goto Y; Yamashita T; Arens M; Takahashi I; [illegible]
SOURCE: JAPANESE JOURNAL OF MEDICAL SCIENCE AND BIOLOGY, (1984
Feb)
37 (1) 9-18.
Journal code: KLT. ISSN: 0021-5112.
PUB. COUNTRY: Japan
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 1984[illegible]

AB Hepatitis B virus (HBV) particles were separated from the plasma containing HBe and HBs antigens (subtype adr), and the nature of the endogenous DNA **polymerase** in the HBV core particles was studied. The HBV endogenous DNA **polymerase** activity was examined under the conditions used for preparation of **HBV vaccine.** The endogenous **DNA polymerase** activity was reduced slowly upon the heat treatment or the formalin treatment. The reductions of the activity were 65% and [illegible]% upon the heat treatment at 60 °C for 10
hr
and the formalin treatment at 37 °C for 72 hr, respectively. Properties of the HBV endogenous DNA **polymerase** were studied by utilizing specific inhibitors against the eukaryotic DNA **polymerases**. Our results showed that the HBV endogenous DNA **polymerase** is resistant to aphidicolin and N-ethylmaleimide, and sensitive to 2',3'-dideoxythymidine 5'-triphosphate, phosphonoformic acid and 9-beta-D-arabinofuranosyladenosine 5'-triphosphate.

L[illegible] ANSWER 3 OF 9 USPATFULL
ACCESSION NUMBER: 97:[illegible] USPATFULL
TITLE: Hepatitis C immunoassays
INVENTOR(S): Houghton, Michael, Danville, CA, United States
Choo, Qui-Lim, El Cerrito, CA, United States
Kuo, George, San Francisco, CA, United States
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States
(U.S.
corporation)

	NUMBER	DATE
PATENT INFORMATION:	US [illegible]	[illegible]
APPLICATION INFO.:	US 1994-[illegible]	1994[illegible] (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-10[illegible], filed on [illegible]
Aug
1993, now patented, Pat. No. US 53[illegible] which is a continuation of Ser. No. US 1989-45[illegible], filed on 21 Dec 1989, now abandoned which is a
continuation-in-part
of Ser. No. US 1989-355002, filed on 18 May 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-341334, filed on 11 Apr 1988, now abandoned
And
Ser. No. US [illegible], filed on [illegible] Mar [illegible], now abandoned, and Ser. No. [illegible] which is a continuation-in-part of Ser. No. US [illegible], filed on 14 Nov [illegible], now abandoned which is a continuation-in-part of Ser. No. US [illegible], filed on [illegible], now abandoned which is a continuation-in-part of Ser. No. US [illegible], filed on [illegible] May [illegible], now abandoned which is a continuation-in-part of Ser. No. US [illegible], filed

```
                         on 26 Feb 1988, now abandoned which is a
                         continuation-in-part of Ser. No. US 1987-139886, filed
                         on 30 Dec 1987, now abandoned which is a
                         continuation-in-part of Ser. No. US 1987-122714, filed
                         on 18 Nov 1987, now abandoned
DOCUMENT TYPE:           Utility
PRIMARY EXAMINER:        Knode, Marian C.
ASSISTANT EXAMINER:      Wortman, Donna C.
LEGAL REPRESENTATIVE:    Murphy, Gladys H.; Harbin, Alisa A.; Blackburn, Robert
                         P.
NUMBER OF CLAIMS:        [illegible]
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      [illegible] Drawing Figure(s); [illegible] Drawing Page(s)
LINE COUNT:              [illegible]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       A family of cDNA sequences derived from hepatitis C virus (HCV) are
         provided. These sequences encode antigens which react immunologically
         with antibodies present in individuals with non-A non-B hepatitis
         (NANBH), but which are absent from individuals infected with hepatitis
A
         virus, or hepatitis B virus, and also are absent in control
individuals.
         The HCV cDNA sequences lack substantial homology to the sequences of
         hepatitis delta virus (HDV) and HBV. A comparison of the sequences of
         amino acids encoded in the HCV cDNA with the sequences of Flaviviruses
         indicates that HCV may be related to the Flaviviruses.

         The HCV cDNA sequences and the polypeptides encoded therein are useful
         as reagents for the detection and therapy of HCV. The reagents provided
         in the invention are also useful for the isolation of NANBH agent(s),
         for the propagation of these agents in tissue culture, and for the
         screening of antiviral agents for HCV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27  ANSWER 7 OF 9  USPATFULL
ACCESSION NUMBER:        97:112[illegible]  USPATFULL
TITLE:                   Method of ordering sequence binding preferences of a
                         DNA-binding molecule
INVENTOR(S):             Edwards, Cynthia A., Menlo Park, CA, United States
                         Fry, Kirk E., Palo Alto, CA, United States
                         Cantor, Charles R., Boston, MA, United States
                         Andrews, Beth M., Maynard, MA, United States
PATENT ASSIGNEE(S):      Genelabs Technologies, Inc., Redwood City, CA, United
                         States (U.S. corporation)

                              NUMBER         DATE
                         --------------- --------
PATENT INFORMATION:      US [illegible]      [illegible]
APPLICATION INFO.:       US [illegible]      [illegible]
DISCLAIMER DATE:         [illegible]
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 1991-[illegible], filed
                         on 27 Jun 1991, now abandoned
DOCUMENT TYPE:           Utility
PRIMARY EXAMINER:        Zitomer, Stephanie W.
ASSISTANT EXAMINER:      Atzel, Amy
LEGAL REPRESENTATIVE:    Fabian, Gary R.; Stratford, Carol A.; Dehlinger, Peter
                         J.
NUMBER OF CLAIMS:        [illegible]
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      48 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT:              [illegible]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       The present invention defines an assay useful for screening libraries
[illegible]
         [illegible]
DNA
```

```
       test sequences. The assay is also useful for determining the sequence
       specificity and relative DNA-binding affinity of DNA-binding molecules
       for any particular DNA sequence. Also described herein are practical
       applications of the assay, including 1) the detection of [illegible]
[illegible]
       through the mass screening of libraries of synthetic or
       biological compounds ([illegible]); 2) the design of
       sequence-specific DNA-binding drugs comprised of homo- or hetero-multi
       multimers of molecules for which the sequence specificity was determined
       using the assay; and 3) the use of molecules for which sequence
       specificity was determined using the assay as covalently attached
       moieties to aid in the binding of nucleic acid or other macromolecular
       polymers to nucleic acid sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

[illegible] ANSWER [illegible] OF [illegible] USPATFULL
ACCESSION NUMBER:        [illegible] USPATFULL
TITLE:                   Sequence-directed DNA-binding molecules compositions
                         and methods
INVENTOR(S):             Edwards, Cynthia A., Menlo Park, CA, United States
                         Cantor, Charles R., Boston, MA, United States
                         Andrews, Beth M., Maynard, MA, United States
                         Turin, Lisa M., Redwood City, CA, United States
                         Fry, Kirk E., Palo Alto, CA, United States
PATENT ASSIGNEE(S):      Genelabs Technologies, Inc., Redwood City, CA, United
                         States (U.S. corporation)

                            NUMBER        DATE
                         --------------- --------
PATENT INFORMATION:      US 5578444      19961126
APPLICATION INFO.:       US 1993-171389  19931220 (8)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 1993-123936, filed
                         on 17 Sep 1993 which is a continuation-in-part of Ser.
                         No. US [illegible], filed on 28 Dec 1990 which is a
                         continuation-in-part of Ser. No. US [illegible], filed
                         on 27 Jun 1991, now abandoned
DOCUMENT TYPE:           Utility
PRIMARY EXAMINER:        Zitomer, Stephanie W.
ASSISTANT EXAMINER:      Atzel, Amy
LEGAL REPRESENTATIVE:    Fabian, Gary R.; Brookes, Allen A.; Stratford, Carol
A.
NUMBER OF CLAIMS:        [illegible]
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      71 Drawing Figure(s); 4[illegible] Drawing Page(s)
LINE COUNT:              [illegible]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       The present invention defines a DNA:protein-binding assay useful for
       screening libraries of synthetic or biological compounds for their
       ability to bind DNA test sequences. The assay is versatile in that any
       number of test sequences can be tested by placing the test sequence
       adjacent to a defined protein binding screening sequence. Binding of
       molecules to these test sequence changes the binding characteristics of
       the protein molecule to its cognate binding sequence. When such a
       molecule binds the test sequence the equilibrium of the DNA:protein
       complexes is disturbed, generating changes in the concentration of free
       DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ
       ID NO:[illegible]) are set forth. The assay of the present invention is also
       useful to characterize the preferred binding sequences of any selected
       DNA-binding molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

[illegible] ANSWER [illegible] OF [illegible] USPATFULL
ACCESSION NUMBER:        [illegible] USPATFULL
TITLE:                   [illegible]
```

```
INVENTOR(S):              Houghton, Michael, Danville, CA, United States
                          Choo, Qui-Lim, El Cerrito, CA, United States
                          Kuo, George, San Francisco, CA, United States
PATENT ASSIGNEE(S):       Chiron Corporation, Emeryville, CA, United States
(U.S.
                          corporation)

                               NUMBER          DATE
                          ---------------- --------
PATENT INFORMATION:       US 5350671       19940927
APPLICATION INFO.:        US 1993-[illegible]    1993[illegible]  (8)
RELATED APPLN. INFO.:     Continuation of Ser. No. US 1989-[illegible], filed on 21
                          Dec 1989, now abandoned which is a
continuation-in-part

                          of Ser. No. US 1989-[illegible], filed on 18 May 1989, now
                          abandoned which is a continuation-in-part of Ser. No.
                          US 1989-341346, filed on 21 Apr 1989, now abandoned
                          which is a continuation-in-part of Ser. No. US
                          1989-341334, filed on 20 Apr 1989, now abandoned which
                          is a continuation-in-part of Ser. No. US 1989-325338,
                          filed on 17 Mar 1989, now abandoned which is a
                          continuation-in-part of Ser. No. US 1988-271450, filed
                          on 14 Nov 1988, now abandoned which is a
                          continuation-in-part of Ser. No. US 1988-263584, filed
                          on 26 Oct 1988, now abandoned which is a
                          continuation-in-part of Ser. No. US 1988-191263, filed
                          on 6 May 1988, now abandoned which is a
                          continuation-in-part of Ser. No. US 1988-161072, filed
                          on 26 Feb 1988, now abandoned which is a
                          continuation-in-part of Ser. No. US 1987-139886, filed
                          on 30 Dec 1987, now abandoned which is a
                          continuation-in-part of Ser. No. US 1987-122714, filed
                          on 18 Nov 1987, now abandoned
DOCUMENT TYPE:            Utility
PRIMARY EXAMINER:         Parr, Margaret
ASSISTANT EXAMINER:       Sisson, Bradley Lounsbury
LEGAL REPRESENTATIVE:     Murphy, Gladys H.; Ciotti, Thomas E.; Blackburn,
Robert
                          P.
NUMBER OF CLAIMS:         41
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       1[illegible] Drawing Figure(s); 100 Drawing Page(s)
LINE COUNT:               7424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Immunoassays for the detection of antibodies to HCV are provided which
         employ "C" domain antigens. Immunoassay kits comprising such antigens
         are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L[illegible]  ANSWER [illegible] OF [illegible]  USPATFULL
ACCESSION NUMBER:         [illegible]  USPATFULL
TITLE:                    Method for immunizing animals with synthetically
                          modified vaccinia virus
INVENTOR(S):              Paoletti, Enzo, Delmar, NY, United States
                          Panicali, Dennis, Averill Park, NY, United States
PATENT ASSIGNEE(S):       Health Research, Incorporated, Albany, NY, United
                          States (U.S. corporation)

                               NUMBER          DATE
                          ---------------- --------
PATENT INFORMATION:       US 4[illegible]       19[illegible]
APPLICATION INFO.:        US 1984-[illegible]    1984[illegible]  (6)
RELATED APPLN. INFO.:     Continuation-in-part of Ser. No. US 1982-445451, filed
                          on 8 Dec 1982, now patented, Pat. No. US 4603112,
                          issued on 29 Jul 1986 which is a continuation-in-part
```

```
                              of Ser. No. US 1981-334456, filed on 24 Dec 1981
DOCUMENT TYPE:                Utility
PRIMARY EXAMINER:             Rosen, Sam
LEGAL REPRESENTATIVE:         Curtis, Morris & Safford
NUMBER OF CLAIMS:             [illegible]
EXEMPLARY CLAIM:              1,[illegible]
NUMBER OF DRAWINGS:           [illegible] Drawing Figure(s); [illegible] Drawing Page(s)
LINE COUNT:                   [illegible]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       What are disclosed are methods for modifying the genome of vaccinia
         virus to produce vaccinia mutants, particularly by the introduction
int
         the vaccinia genome of exogenous DNA; modified vaccinia prepared by
suc
         methods; certain DNA sequences and microorganisms and genetically modified
         microorganisms involved as intermediates in such methods; and methods
         for infecting cells and host animals with such vaccinia mutants to
         provoke the amplification of exogenous DNA and proteins encoded by the
         exogenous DNA, including antigenic proteins, by said cells and host
         animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> vir(5a)DNA Vaccine

VIR(5A)DNA IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s vir(5a)DNA Vaccine

L23             0 VIR(5A) DNA VACCINE

=> s vir?(5a)DNA Vaccin?

   3 FILES SEARCHED...
L24          114[illegible] VIR?(5A) DNA VACCIN?

=> s L24 ad<=19980130

MISSING OPERATOR
MISSING OPERATOR L24 AD<=19980130
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L24 and ad<19980130

   3 FILES SEARCHED...
L25           387 L24 AND AD<19980130

=> L25 and genetic immuni?

L25 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s vir?(5a)genetic Immuni?

   3 FILES SEARCHED...
     FILES SEARCHED...
L26             [illegible] VIR?(5A) GENETIC IMMUNI?

=> s L26 and [illegible]
```

FILES SEARCHED...
[illegible]